Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders

The clinical failure rate for disease-modifying treatments (DMTs) that slow or stop disease progression has been nearly 100% for the major neurodegenerative disorders (NDDs), with many compounds failing in expensive and time-consuming phase 2 and 3 trials for lack of efficacy. Here, we critically re...

Descripción completa

Detalles Bibliográficos
Autores principales: Vissers, Maurits F. J. M., Heuberger, Jules A. A. C., Groeneveld, Geert Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915613/
https://www.ncbi.nlm.nih.gov/pubmed/33562713
http://dx.doi.org/10.3390/ijms22041615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915613/
https://www.ncbi.nlm.nih.gov/pubmed/33562713
http://dx.doi.org/10.3390/ijms22041615

Ejemplares similares